Lucas John T, Faught Austin M, Hsu Chih Yang, Wilson Lydia J, Guo Yian, Li Yimei, Khan Raja, Becksfort Jared B, LeVine David A, Ismael Yousef, Darrow Kaleb, Moskvin Vadim P, Pirlepesov Fakhriddin, Klimo Paul, Elijovich Lucas, Indelicato Daniel J, Boop Fredrick A, Merchant Thomas E
Department of Radiation Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee.
Department of Radiation Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee.
Int J Radiat Oncol Biol Phys. 2022 May 1;113(1):152-160. doi: 10.1016/j.ijrobp.2021.12.172. Epub 2022 Jan 3.
Vasculopathy (VAS) is a significant complication associated with radiation therapy in patients treated for brain tumors. We studied the type, location, severity, timing, and resolution of VAS in children with craniopharyngioma treated with proton radiation therapy (PRT) and evaluated predictors of stenosis (STN) using a novel patient and imaging-based modeling approach.
Children with craniopharyngioma (n = 94) were treated with 54 Gy relative biological effectiveness PRT in a clinical trial, NCT01419067. We evaluated VAS type, location, severity, and resolution. VAS events were segmented and related to their location, operative corridor, PRT dose, and vascular territory to facilitate mixed effect logistic regression modeling of spatial predictors of STN events.
Forty-five (47.9%) patients had 111 instances of confirmed VAS (pre-PRT n = 37, 33.3%). The median time to post-PRT VAS was 3.41 years (95% confidence interval, 1.86-6.11). STN events were observed post-PRT in 23.4% (n = 22) of patients. Post-PRT VAS was detected by cerebral angiogram in 9.6% (n = 9), severe in 4.3% (n = 4), and compensated on perfusion in 2.1% (n = 2). Revascularization was required for 5 (5.3%) patients. Postsurgical, pre-PRT VAS, and PRT dose to unperturbed vessels were predictive of STN. The effect of PRT on STN was negligible within the surgical corridor.
VAS often precedes PRT and was the strongest predictor of post-PRT STN. The adverse effect of PRT on STN was only apparent in unperturbed vasculature beyond the operative corridor.
血管病变(VAS)是脑肿瘤患者放射治疗相关的一种重要并发症。我们研究了接受质子放射治疗(PRT)的颅咽管瘤患儿VAS的类型、位置、严重程度、发生时间及消退情况,并采用一种基于患者和影像学的新型建模方法评估狭窄(STN)的预测因素。
在一项临床试验(NCT01419067)中,94例颅咽管瘤患儿接受了相对生物效应为54 Gy的PRT治疗。我们评估了VAS的类型、位置、严重程度及消退情况。对VAS事件进行分割,并将其与位置、手术通道、PRT剂量及血管区域相关联,以促进对STN事件空间预测因素的混合效应逻辑回归建模。
45例(47.9%)患者出现111例确诊的VAS(放疗前37例,33.3%)。放疗后出现VAS的中位时间为3.41年(95%置信区间,1.86 - 6.11)。23.4%(n = 22)的患者在放疗后观察到STN事件。脑血管造影检测到放疗后VAS的占9.6%(n = 9),严重的占4.3%(n = 4),灌注代偿性改变的占2.1%(n = 2)。5例(5.3%)患者需要进行血管重建。术后、放疗前VAS以及未受干扰血管的PRT剂量是STN的预测因素。在手术通道内,PRT对STN的影响可忽略不计。
VAS常发生在PRT之前,是放疗后STN的最强预测因素。PRT对STN的不良影响仅在手术通道以外未受干扰的脉管系统中明显。